(redirected from HTLV-I)
Also found in: Dictionary, Thesaurus, Medical, Acronyms, Encyclopedia, Wikipedia.
Related to HTLV-I: Human T-lymphotropic virus
See: disease
References in periodicals archive ?
Within the United States, intravenous drug abusers currently exhibit the highest HTLV-I infection rates, ranging from 7 percent to 49 percent depending upon geographical location.
HTLV-II is related to HTLV-I and is endemic in several Amerindian tribes but has not been unequivocally proven to be a pathogen.
Approving a test for HTLV-I is one of our highest priorities now," says FDA Commissioner Young.
HTLV-I "indeterminate'" Western blot patterns observed in sera from tropical regions: the situation revisited.
HTLV-I has been causally associated with adult T-cell leukemia and HTLV-associated myelopathy.
HTLV-I is a retrovirus known to cause a rare form of leukemia and
The new virus differs from the other two "cancer' retroviruses in that the cancer cells from HTLV-V infected patients do not have two specific surface receptors found on cancer cells from patients infected with HTLV-I and -II, say the authors.
In addition to its vaccine for HTLV-II, the Company is developing a vaccine for HTLV-I and an animal model of HIV infection.
However, unpublished results from NCI say that HTLV-I is spreading through urban populations of intravenous drug abusers, a group considered at risk for AIDS.
Food and Drug Administration (FDA) has approved the company's product licensure application (PLA) for its HTLV-I (rp21e enhanced) immunoassay, an improved sensitivity blood screening test for Human T-Lymphotropic Virus Type I (HTLV-I).
Virologix: Virologix is a privately held pharmaceutical company focused on the development of treatments for HIV and vaccines to prevent HTLV-I and HTLV-II infection.